Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.

@article{Warn2012AnidulafunginFN,
  title={Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.},
  author={Peter A. Warn and Joanne Livermore and Susan Julie Howard and Timothy W Felton and Andrew D. Sharp and Lea Gregson and Joanne Goodwin and Ruta Petraitiene and Vidmantas Petraitis and Michael Cohen-Wolkowiez and Thomas J Walsh and Daniel Kelly Benjamin and William W Hope},
  journal={Antimicrobial agents and chemotherapy},
  year={2012},
  volume={56 2},
  pages={708-14}
}
Hematogenous Candida meningoencephalitis (HCME) is a serious infection in premature neonates. Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp., but its efficacy and optimal regimens for human neonates with HCME are not known. A well-validated rabbit model of HCME was used to define pharmacokinetic-pharmacodynamic (PK-PD) relationships of anidulafungin. A mathematical model was fitted to the entire data set. The experimental data were bridged to humans… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…